The RNA-guided endonuclease Cas9 has emerged as a versatile genome-editing platform. However, the size of the commonly used Cas9 from Streptococcus pyogenes (SpCas9) limits its utility for basic research and therapeutic applications that use the highly versatile adeno-associated virus (AAV) delivery vehicle. Here, we characterize six smaller Cas9 orthologues and show that Cas9 from Staphylococcus aureus (SaCas9) can edit the genome with efficiencies similar to those of SpCas9, while being more than 1 kilobase shorter. We packaged SaCas9 and its single guide RNA expression cassette into a single AAV vector and targeted the cholesterol regulatory gene Pcsk9 in the mouse liver. Within one week of injection, we observed .40% gene modification, accompanied by significant reductions in serum Pcsk9 and total cholesterol levels. We further assess the genome-wide targeting specificity of SaCas9 and SpCas9 using BLESS, and demonstrate that SaCas9-mediated in vivo genome editing has the potential to be efficient and specific.
The RNA-guided endonuclease Cas9 has emerged as a versatile genome-editing platform. However, the size of the commonly used Cas9 from Streptococcus pyogenes (SpCas9) limits its utility for basic research and therapeutic applications that use the highly versatile adeno-associated virus (AAV) delivery vehicle. Here, we characterize six smaller Cas9 orthologues and show that Cas9 from Staphylococcus aureus (SaCas9) can edit the genome with efficiencies similar to those of SpCas9, while being more than 1 kilobase shorter. We packaged SaCas9 and its single guide RNA expression cassette into a single AAV vector and targeted the cholesterol regulatory gene Pcsk9 in the mouse liver. Within one week of injection, we observed .40% gene modification, accompanied by significant reductions in serum Pcsk9 and total cholesterol levels. We further assess the genome-wide targeting specificity of SaCas9 and SpCas9 using BLESS, and demonstrate that SaCas9-mediated in vivo genome editing has the potential to be efficient and specific.
Cas9, an RNA-guided endonuclease derived from the type II CRISPR-Cas bacterial adaptive immune system [1] [2] [3] [4] [5] [6] [7] , has been harnessed for genome editing 8, 9 and holds tremendous promise for biomedical research. Genome editing of somatic tissue in postnatal animals, however, has been limited in part by the challenge of delivering Cas9 in vivo. For this purpose, adeno-associated virus (AAV) vectors are attractive vehicles 10 because of their low immunogenic potential, reduced oncogenic risk from host-genome integration 11 , and broad range of serotype specificity [12] [13] [14] [15] . Nevertheless, the restrictive cargo size (,4.5 kb, excluding the inverted terminal repeats) of AAV presents an obstacle for packaging the commonly used Streptococcus pyogenes Cas9 (SpCas9, ,4.2 kb) and its single guide RNA (sgRNA) in a single vector; although technically feasible 17 , this approach leaves little room for customized expression and control elements 16 .
In search of smaller Cas9 enzymes for efficient in vivo delivery by AAV, we have previously described a short Cas9 from the CRISPR1 locus of Streptococcus thermophilus LMD-9 (St1Cas9, ,3.3 kb) 8 as well as a rationally-designed truncated form of SpCas9 (ref. 18 ) for genome editing in human cells. However, both systems have important practical drawbacks: the former requires a complex protospacer-associated motif (PAM) sequence (NNAGAAW) 3 , which restricts the range of accessible targets, whereas the latter exhibits reduced activity. Given the substantial diversity of CRISPR-Cas systems present in sequenced microbial genomes 19 , we therefore sought to interrogate and discover additional Cas9 enzymes that are small, efficient and broadly targeting.
In vitro cleavage by small Cas9 enzymes
Type II CRISPR-Cas systems require only two main components for eukaryotic genome editing: a Cas9 enzyme, and a chimaeric sgRNA 6 derived from the CRISPR RNA (crRNA) and the noncoding transactivating crRNA (tracrRNA) 4, 20 . Analysis of over 600 Cas9 orthologues shows that these enzymes are clustered into two length groups with characteristic protein sizes of approximately 1,350 and 1,000 amino acid residues, respectively 19, 21 (Extended Data Fig. 1a ), with shorter Cas9 enzymes having significantly truncated REC domains (Fig. 1a ). From these shorter Cas9 enzymes, which belong to Type IIA and IIC subtypes, we selected six candidates for profiling ( Fig. 1a and Extended Data Fig. 1b ). To determine the cognate crRNA and tracrRNA for each Cas9, we computationally identified regularly interspaced repeat sequences (direct repeats) within a 2-kb window flanking the CRISPR locus. We then predicted the tracrRNA by detecting sequences with strong complementarity to the direct repeat sequence (an anti-repeat region), at least two predicted stem-loop structures, and a Rho-independent transcriptional termination signal up to 150 nucleotides downstream of the anti-repeat region. Although a truncated tracrRNA can support robust DNA cleavage in vitro 6 , previous reports show that the secondary structures of the tracrRNA are important for Cas9 activity in mammalian cells 8, 9, 18, 22 . Therefore, we designed sgRNA scaffolds for each orthologue by fusing the 39 end of a truncated direct repeat with the 59 end of the corresponding tracrRNA, including the full-length tail, via a 4-nucleotide linker 6 (Extended Data Fig. 1b and Supplementary Table  1 ). To identify the PAM sequence for each Cas9, we first constructed a library of plasmid DNA containing a constant 20-bp target followed by a degenerate 7-bp sequence (59-NNNNNNN). We then incubated cell lysate from human embryonic kidney 293FT (293FT) cells expressing the Cas9 orthologue with its in vitro-transcribed sgRNA and the plasmid library. By generating a consensus from the 7-bp sequence found on successfully cleaved DNA plasmids ( Fig. 1b ), we determined putative PAMs for each Cas9 (Fig. 1c ). We observed that, similar to SpCas9, most Cas9 orthologues cleaved targets 3-bp upstream of the PAM (Extended Data Fig. 2 ). To validate each putative PAM from the library, we then incubated a DNA template bearing the consensus PAM with cell lysate and the corresponding sgRNA. We found that the Cas9 orthologues, in combination with the sgRNA designs, successfully cleaved the appropriate targets ( Fig. 1d and Supplementary Table 2 ).
To test whether each Cas9 orthologue can facilitate genome editing in mammalian cells, we co-transfected 293FT cells with individual Cas9 enzymes and their respective sgRNAs targeting human endogenous loci containing the appropriate PAMs. Of the six Cas9 orthologues tested, only the one from Staphylococcus aureus (SaCas9) produced indels with efficiencies comparable to those of SpCas9 (Extended Data Fig. 3a, b and Supplementary Table 3 ), suggesting that DNA-cleavage activity in cell-free assays does not necessarily predict activity in mammalian cells. These observations prompted us to focus on harnessing SaCas9 and its sgRNA for in vivo applications.
SaCas9 sgRNA design and PAM discovery
Although mature crRNAs in S. pyogenes are processed to contain 20nucleotide spacers (guides) and 19-to 22-nucleotide direct repeats 4 , RNA sequencing of crRNAs from other organisms reveals that the spacer and direct repeat sequence lengths can vary 4, 20, 23 . We therefore tested sgRNAs for SaCas9 with variable guide lengths and repeat:anti-repeat duplexes. We found that SaCas9 achieves the highest editing efficiency in mammalian cells with guides between 21 and 23 nucleotides long and can accommodate a range of lengths for the direct repeat:anti-repeat region ( Fig. 2a , b, Extended Data Fig. 4 ). This notably contrasts with SpCas9, where the natural 20-nucleotide guide length can be truncated to 17 nucleotides without significantly compromising nuclease activity, while increasing specificity 24 . Additionally, replacing the first base of the guide with guanine further improved SaCas9 activity (Extended Data Fig. 3c ).
To fully characterize the SaCas9 PAM and the seed region within its guide sequence 25 , we performed chromatin immunoprecipitation (ChIP) using catalytically mutant forms of SaCas9 (dSaCas9, D10A and N580A mutations, based on homology to SpCas9) or SpCas9 (dSpCas9, D10A and H840A mutations) and their corresponding sgRNAs. We targeted two loci in the human EMX1 gene with composite NGGRRT PAMs, which allow targeting by both dCas9s. A search for motifs containing both the guide region and PAM within 50 nucleotides of the ChIP peak summits revealed seed sequences of 7-8 nucleotides for dSaCas9 ( Fig. 2c ). In addition, NNGRRT and NGG PAMs were found adjacent to the seed sequences for dSaCas9 and dSpCas9, respectively (Extended Data Fig. 5 ). Although the 6th position of the PAM is predominantly thymine, we did observe low levels of degeneracy in both the biochemical and ChIP-based PAM discovery assays ( Fig. 1c and Extended Data Fig. 5a ). We therefore tested the base preference for this position and determined that, although SaCas9 cleaves genomic targets most efficiently with NNGRRT, all NNGRR PAMs can be cleaved and should be considered as potential targets, especially in the context of off-target evaluations ( Fig. 2d , Extended Data Fig. 6 and Supplementary Table 4 ).
Unbiased profiling of Cas9 specificity
As advances in Cas9 technology promise to enable a broad range of in vivo and therapeutic applications, accurate, genome-wide identification of off-target nuclease activity has become increasingly important. Although a number of studies have employed sequence similarity-based off-target search 22, [26] [27] [28] [29] [30] or dCas9-ChIP 31, 32 to predict off-target sites for Cas9, such approaches cannot assess the nuclease activity of Cas9 in a comprehensive and unbiased manner. To measure the genome-wide a 1 cleavage activity of SaCas9 and SpCas9 directly, we applied BLESS (direct in situ breaks labelling, enrichment on streptavidin and next-generation sequencing) 33 to capture a snapshot of Cas9-induced DNA doublestranded breaks (DSBs) in cells. We transfected 293FT cells with SaCas9 or SpCas9 and the same EMX1 targeting guides used in the previous ChIP experiment, or pUC19 as a negative control. After cells are fixed, free genomic DNA ends from DSBs are captured using biotinylated adaptors and analysed by deep sequencing (Fig. 3a) . To identify candidate Cas9-induced DSB sites genome-wide, we established a three-step analysis pipeline following alignment of the sequenced BLESS reads to the genome (Extended Data Fig. 7a , Supplementary  Discussion) . First, we applied nearest-neighbour clustering on the aligned reads to identify groups of DSBs (DSB clusters) across the genome. Second, we sought to separate potential Cas9-induced DSB clusters from background DSB clusters resulting from low frequency biological processes and technical artefacts, as well as high-frequency telomeric and centromeric DSB hotspots 33 . From the on-target and a small subset of verified off-target sites (predicted by sequence similarity using a previously established method 22 and sequenced to detect indels), we found that reads in Cas9-induced DSB clusters mapped to characteristic, well-defined genomic positions compared to the more diffuse alignment pattern at background DSB clusters. To distinguish between the two types of DSB clusters, we calculated in each cluster the distance between all possible pairs of forward and reverse-oriented reads (corresponding to 39 and 59 ends of DSBs), and filtered out the background DSB clusters based on the distinctive pairwise-distance distribution of these clusters (Extended Data Fig. 7b, c) . Third, the DSB score for a given locus was calculated by comparing the count of DSBs in the experimental and negative control samples using a maximum-likelihood estimate 22 (Supplementary Discussion). This analysis identified the on-target loci for both SaCas9 and SpCas9 guides as the top scoring sites, and revealed additional sites with high DSB scores ( Fig. 3b-d ).
Next, we sought to assess whether DSB scores correlated with indel formation. We used targeted deep sequencing to detect indel formation on the ,30 top-ranking off-target sites identified by BLESS for each Cas9 and sgRNA combination. We found that only those sites that contained PAM and homology to the guide sequence exhibited indels (Extended Data Fig. 8 ). We observed a strong linear correlation between DSB scores and indel levels for each Cas9 and sgRNA pairing (r 2 5 0.948 and 0.989 for the two EMX1 targets with SaCas9 and r 2 5 0.941 and 0.753 for those with SpCas9) (Fig. 3c , Extended Data Fig. 9b-d) . Furthermore, BLESS identified additional off-target sites not previously predicted by sequence similarity to target or ChIP (Extended Data Figs 7 and 9, Supplementary Tables 5 and 6 ). These new off-target sites include not only those containing Watson-Crick base-pairing mismatches to the guide, but also the recently reported insertion and deletion mismatches in the guide:target heteroduplex (Fig. 3d) 29, 30 . Together, these results highlight the need for more precise understanding of rules governing Cas9 nuclease activity, a requisite step towards improving the predictive power of computational guide design programs.
In vivo genome editing using SaCas9
Following in vitro characterization, we incorporated SaCas9 and its sgRNA into an AAV vector to test its efficacy and specificity in vivo.
The small size of SaCas9 enables packaging of both a U6-driven sgRNA and a cytomegalovirus (CMV)-or thyroxine-binding globulin (TBG)-driven SaCas9 expression cassette into a single AAV vector within the 4.5-kb packaging limit. Using hepatocytetropic AAV serotype 8, we targeted the mouse apolipoprotein (Apob) gene (Extended Data Fig. 10a ). One week after intravenous administration of virus into C57BL/6 mice, we observed ,5% indel formation in liver tissue; after four weeks, the liver tissue showed characteristic hepatic lipid accumulation from Apob knockdown following histology analysis using oil red staining [34] [35] [36] [37] (Extended Data Fig. 10b, c) . We next targeted proprotein convertase subtilisin/kexin type 9 (Pcsk9), a therapeutically relevant gene involved in cholesterol homeostasis 38 . Inhibitors of the human convertase PCSK9 have emerged as a promising new class of cardioprotective drugs, after human genetic studies revealed that loss of PCSK9 is associated with a reduced risk of cardiovascular disease and lower levels of low-density lipoprotein (LDL) cholesterol [39] [40] [41] . We designed two Pcsk9-targeting sgRNAs (20-nucleotide guides with additional 59 guanine) and validated their activity in vitro. Each sgRNA was packaged into AAV-SaCas9 and injected into mice (2 3 10 11 total genome copies) ( Fig. 4a ). One week after administration, we observed greater than 40% indel formation at either locus in whole liver tissue, with similar levels two and four weeks post-injection (Fig. 4b) .
To determine the effect of Pcsk9-targeting AAV-SaCas9 dosage on serum Pcsk9 and total cholesterol levels, we administered a range of AAV titres from 0.5 3 10 11 to 4 3 10 11 total genome copies. With all titres, we observed a ,95% decrease in serum Pcsk9 and a ,40% decrease in total cholesterol one week after administration, both of which were sustained throughout the course of four weeks (Fig. 4c, d ). 
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We next considered SaCas9 off-target modifications in the liver tissue samples. To first identify candidate off-target cleavage sites for the two Pcsk9-targeting guides, we transiently transfected an AAV-CMV::SaCas9 vector into mouse Neuroblastoma-2a (N2a) cells and applied BLESS to detect Cas9-induced DSBs in the genome. For both guides, we found very low levels of DSB signal across the genome except at the on-target loci (Fig. 4e ). Targeted deep sequencing of the candidate off-target sites identified by BLESS in N2a cells did not reveal appreciable levels of indels in either N2a cells or liver tissue (4 weeks post injection of 2 3 10 11 total genome copies) (Fig. 4e, f and Supplementary Table 8 ). We additionally sequenced off-target sites predicted by target sequence similarity, and likewise did not detect indel formations ( Supplementary  Table 9 ).
Finally, we examined the titre-matched Pcsk9-targeting and enhanced green fluorescent protein-conjugated (EGFP) TBG-EGFP cohorts as well as naive animals for signs of toxicity or acute immune response. At 1 week post-injection, necropsy and gross examination of liver tissue of the cohorts revealed no abnormalities; further histological examination of the liver by haematoxylin and eosin (H&E) staining showed no signs of inflammation, such as aggregates of lymphocytes or macrophages ( Fig. 5a ). Throughout the time course of the experiment, there were no elevated levels of serum alanine aminotransferase (ALT), albumin, and total bilirubin in any of the cohorts. We observed a slight trend in aspartate transaminase (AST) increase across all cohorts at four weeks, including the uninjected animals. The elevated levels did not exceed the upper limit of normal and is not indicative of hepatocellular injury in animals (Fig. 5b ). However, a larger cohort study should be conducted to further evaluate the potential side-effects of Cas9-mediated in vivo genome editing. In addition, the differences between mouse and human immune responses need to be better elucidated before considering this approach for therapeutic applications.
Discussion
Here, we develop a small and efficient Cas9 from S. aureus for in vivo genome editing 17 . The results of these experiments highlight the power of using comparative genomic analysis 19, 42 in expanding the CRISPR-Cas9 toolbox. Identification of new Cas9 orthologues 19, 42 , in addition to structure-guided engineering, could yield a repertoire of Cas9 variants with expanded capabilities and minimized molecular weight, for nucleic acid manipulation to further advance genome and epigenome engineering.
The AAV-SaCas9 system is able to mediate efficient and rapid editing of Pcsk9 in the mouse liver, resulting in reductions of serum Pcsk9 and total cholesterol levels. To assess the specificity of SaCas9, we used an unbiased DSB detection method, BLESS, to identify a list of candidate off-target cleavage sites in a mouse cell line. We examined these sites in liver tissue transduced by AAV-SaCas9 and did not observe any indel formation within the detection limits of in vitro BLESS and targeted deep sequencing. Importantly, the off-target sites identified in vitro might differ from those in vivo, which need to be further evaluated by the applications of BLESS or other unbiased techniques such as those published during the revision of this work 43, 44 . Finally, we did not observe any overt signs of acute toxicity in mice at one to four weeks after virus administration. Although more studies are needed to further improve the SaCas9 system for in vivo genome editing, such as assessing the long-term impact of Cas9 and sgRNA expression, these findings suggest that in vivo genome editing using SaCas9 has the potential to be highly efficient and specific.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
METHODS
No statistical methods were used to predetermine sample size.
In vitro transcription and cleavage assay. Cas9 orthologues were human codonoptimized and synthesized by GenScript, and transfected into 293FT cells as described below. Whole-cell lysates from 293FT cells were prepared with lysis buffer (20 mM HEPES, 100 mM KCl, 5 mM MgCl2, 1 mM DTT, 5% glycerol, 0.1% Triton X-100) supplemented with Protease Inhibitor Cocktail (Roche). T7-driven sgRNA was transcribed in vitro using custom oligonucleotides (Supplementary Information) and HiScribe T7 In vitro Transcription Kit (NEB), following the manufacturer's recommended protocol. The in vitro cleavage assay was carried out as follows: for a 20 ml cleavage reaction, 10 ml of cell lysate was incubated with 2 ml cleavage buffer (100 mM HEPES, 500 mM KCl, 25 mM MgCl 2 , 5 mM DTT, 25% glycerol), 1 mg in vitro transcribed RNA and 200 ng EcoRI-linearized pUC19 plasmid DNA or 200 ng purified PCR amplicons from mammalian genomic DNA containing target sequence. After 30 min incubation, cleavage reactions were purified using QIAquick Spin Columns and treated with RNase A at final concentration of 80 ng ml 21 for 30 min and analysed on a 1% agarose E-Gel (Life Technologies).
In vitro PAM screen. Rho-independent transcriptional termination was predicted using the ARNold terminator search tool 46, 47 . For the PAM library, a degenerate 7-bp sequence was cloned into a pUC19 vector. For each orthologue, the in vitro cleavage assay was carried out as above with 1 mg T7-transcribed sgRNA and 400 ng pUC19 with degenerate PAM. Cleaved plasmids were linearized by NheI, gel extracted, and ligated with Illumina sequencing adaptors. Barcoded and purified DNA libraries were quantified by Quant-iT PicoGreen dsDNA Assay Kit or Qubit 2.0 Fluorometer (Life Technologies) and pooled in an equimolar ratio for sequencing using the Illumina MiSeq Personal Sequencer (Life Technologies). MiSeq reads were filtered by requiring an average Phred quality (Q score) of at least 23, as well as perfect sequence matches to barcodes. For reads corresponding to each orthologue, the degenerate region was extracted. All extracted regions were then grouped and analysed with Weblogo 45 .
Cell culture and transfection. Human embryonic kidney 293FT (Life Technologies), Neuro-2a (N2a), and Hepa1-6 (ATCC) cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% FBS (HyClone), 2 mM GlutaMAX (Life Technologies), 100 U ml 21 penicillin, and 100 mg ml 21 streptomycin at 37 uC with 5% CO 2 incubation. Cells were seeded into 24-well plates (Corning) one day before transfection at a density of 240,000 cells per well, and transfected at 70-80% confluency using Lipofectamine 2000 (Life Technologies) following the manufacturer's recommended protocol. For each well of a 24-well plate, a total of 500 ng DNA was used. For ChIP and BLESS, a total of 4.5 million cells are seeded the day before transfection into a 100-mm plate, and a total of 20 mg DNA was used. DNA isolation from cells and tissue. Genomic DNA was extracted using the QuickExtract DNA Extraction Solution (Epicentre). Briefly, pelleted cells were resuspended in QuickExtract solution and incubated at 65 uC for 15 min, 68 uC for 15 min, and 98 uC for 10 min (ref. 8) . Genomic liver DNA was extracted from bulk tissue fragments using a microtube bead mill homogenizer (Beadbug, Denville Scientific) by homogenizing approximately 30-50 mg of tissue in 600 ml of DPBS (Gibco). The homogenate was then centrifuged at 2,000 to 3,000g for 5 min at 4 uC and the pellet was resuspended in 300-600 ml QuickExtract DNA Extraction Solution (Epicentre) and incubated as above. Indel analysis and guide:target base-pairing mismatch search. Indel analyses by SURVEYOR assay and targeted deep sequencing were carried out and analysed as previously described 8, 22 . The methods for identification of potential off-target sites for SpCas9 based on Watson-Crick base-pairing mismatch between guide RNA and target DNA has been previously described 22 , and adapted for SaCas9 by considering NNGRR for possible off-target PAMs. Alignment was manually adjusted to allow for insertion and deletion mismatches in the guide:target heteroduplex 29, 30 . Chromatin immunoprecipitation and analysis. Cells were passaged at 24 h posttransfection into a 150-mm dish, and fixed for ChIP processing at 48 h posttransfection. For each condition, 10 million cells are used for ChIP input, following experimental protocols and analyses as previously described 31 with the following modifications: instead of pairwise peak-calling, ChIP peaks were only required to be enriched over both 'empty' controls (dSpCas9 only, dSaCas9 only) as well as the other Cas9/other sgRNA sample (for example, SpCas9/EMX-sg2 peaks must be enriched over SaCas9/EMX-sg1 peaks in addition to the empty controls). This was done to avoid filtering out of real peaks present in two related samples as much as possible.
To identify off-targets ranked by motif or sequence similarity to guide, motif scores for ChIP peaks were calculated as follows: for a given ChIP peak, the 100nucleotide interval around the peak summit, the target sequence, and a given sgRNA guide region of length L, the query, an alignment score is calculated for every subsequence of L in the target. The subsequence with the highest score is reported as the best match to the query. For each subsequence alignment, the score calculation begins at the 59 end of the query. For each position in the alignment, 1 is added or subtracted for match or mismatch between the query and target, respectively. If the score becomes negative, it is set to 0 and the calculation continued for the remainder of the alignment. The score at the 39 end of the query is reported as the final score for the alignment. MACS scores 5 210log(P value relative to the empty control) are determined as previously described 48 . For unbiased determination of PAM from ChIP peaks, the peaks were analysed for the best match by motif score to the guide region only within 50 nucleotides of the peak summit; the alignment was extended for 10 nucleotides at the 39 end and visualized using Weblogo 45 .
To calculate the motif score threshold at which false discovery rate , 0.1 for each sample, 100-nucleotide sequences centred around peak summits were shuffled while preserving dinucleotide frequency. The best match by motif score to the guide1PAM (NGG for SpCas9, NNGRRT for SaCas9) in these shuffled sequences was then found. The score threshold for false discovery rate , 0.1 was defined as the score such that less than 10% of shuffled peaks had a motif score above that score threshold. BLESS for DSB detection. Cells are harvested at 24 h post-transfection, then processed as previously described 33 with the following alterations: a total of 10 million cells are fixed for nuclei isolation and permeabilization, and treated with Proteinase K for 4 min at 37 uC before inactivation with PMSF. All deproteinized nuclei are used for DSB labelling with 100 mM of annealed proximal linkers overnight. After Proteinase K digestion of labelled nuclei, chromatin was mechanically sheared with a 26G needle before sonication (BioRuptor, 20 min on high, 50% duty cycle). 20 mg of sheared chromatin are captured on streptavidin beads, washed, and ligated to 200 mM of distal linker. Linker hairpins are then cleaved off with I-SceI digestion for 1 h at 37 uC, and products PCR-enriched for 18 cycles before proceeding to library preparation with TruSeq Nano LT Kit (Illumina). For the negative control, cells mock transfected with Lipofectamine 2000 and pUC19 DNA were parallel processed through the assay. BLESS analysis. Fastq files were demultiplexed, and 30-bp genomic sequences were separated from the BLESS ligation handles for alignment. Bowtie was used to map the genomic sequences to hg19 or mm9, allowing for a maximum of 2 mismatches. Following alignment, reads from all bio-replicates for an individual sample were first pooled, and then nearest neighbour clustering was performed with a 30-bp moving window to identify regions of enrichment across the genome. Within each cluster, the pairwise distance was calculated between all forward and reverse read strand mappings (Extended Data Fig. 7b, c) . Pairwise distance distributions were used to filter out wide and poorly defined DSB clusters from the well-defined DSB clusters characteristically found at Cas9-induced cleavage sites (see Supplementary  Information) . Finally, we adjusted the count of predicted Cas9-induced DSBs at a given locus by using a binomial model to calculate the maximum-likelihood estimate of peak enrichment in the Cas9-sgRNA treated sgRNAs given BLESS measurements from an untreated negative control. After the maximum-likelihood estimate calculation, a list of loci ranked by their DSB scores could be obtained and plotted (Fig. 3b, Extended Data Fig. 8 ). Additional descriptions can be found in Supplementary Information.
The top-ranking ,30 sites from the list of Cas9 induced DSB clusters were sequenced for indel formation (Extended Data Fig. 8 ; validated targets in Fig. 3d ). Within these loci, PAMs and regions of target homology were identified by first searching all PAM sites within a 6 50 bp window around the DSB cluster, then selecting the adjacent sequence with fewest mismatches to the target sequence. Code availability. BLESS analysis code is available at https://github.com/fengzhanglab/BLESS. Virus production and titration. For in-house viral production, 293FT cells (Life Technologies) were maintained as described above in 150 mm plates. For each transfection, 8 mg of pAAV8 serotype packaging plasmid, 10 mg of pDF6 helper plasmid, and 6 mg of AAV2 plasmid carrying the construct of interest were added to 1mL of serum-free DMEM. 125 ml of PEI ''Max'' solution (1 mg ml -1 , pH 5 7.1) was then added to the mixture and incubated at room temperature for 5 to 10 s. After incubation, the mixture was added to 20 ml of warm maintenance media and applied to each dish to replace the old growth media. Cells were harvested between 48 h and 72 h post transfection by scraping and pelleting by centrifugation. The AAV2/8 (AAV2 inverted terminal repeat (ITR) vectors pseudo-typed with AAV8 capsid) viral particles were then purified from the pellet according to a previously published protocol 49 .
High titre and purity viruses were also produced by vector core facilities at Children's Hospital Boston and Massachusetts Eye and Ear Infirmary (MEEI). These AAV vectors were then titred by real-time qPCR using a customized TaqMan probe against the transgene, and all viral preparations were titre-matched across different batches and production facilities before experiments. The purity of AAV vector was further verified by SDS-PAGE.
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Animal injection and processing. All mice cohorts were maintained at animal facility with standard diet and housing following IRB-approved protocols. AAV vector was delivered to 5-6 week old male C57/BL6 mice intravenously via lateral tail vein injection. All dosages of AAV were adjusted to 100 ml or 200 ml with sterile phosphate buffered saline (PBS), pH 7.4 (Gibco) before the injection. Animals were not immunosuppressed or otherwise handled differently before injection or during the course of the experiment except the pre-bleed fasting as noted below. The animals were randomized to the different experimental conditions, with the investigator not blinded to the assignments.
To track the serum levels of Pcsk9 and total cholesterol, animals were fasted overnight for 12 h before blood collection by saphenous vein bleeds (no more than 100 ml or 10% of total blood volume per week). Multiple bleeds were made before tail vein delivery of AAV vector or control to collect pre-injection samples and to habituate the animals to handling during the procedure. After the blood was allowed to clot at room temperature, the serum was separated by centrifugation and stored at -20 uC for subsequent analysis. For terminal procedures to collect liver tissue and larger serum volumes for chemistry panels, mice were euthanized by carbon dioxide inhalation. Subsequently, blood was collected via cardiac puncture. Transcardial perfusion with 30 ml PBS removed the remaining blood, after which liver samples were collected. The median lobe of liver was removed and fixed in 10% neutral buffered formalin for histological analysis, while the remaining lobes were sliced in small blocks of size less than 1 3 1 3 3 mm 3 and frozen for subsequent DNA or protein extraction.
